The Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 Experts
In the preceding three months, 4 analysts have released ratings for CARISMA Therapeutics (NASDAQ:CARM), presenting a wide array…
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 6.7% to $0.26 during Wednesday’s after-market session. The company’s market…
Benzinga’s Top Ratings Upgrades, Downgrades For October 3, 2023
Upgrades For Kellanova Co (NYSE:K), Exane BNP Paribas upgraded the previous rating of Underperform to Neutral. Kellanova earned…
The Latest Analyst Ratings for CARISMA Therapeutics
Analysts have provided the following ratings for CARISMA Therapeutics (NASDAQ:CARM) within the last quarter: Bullish Somewhat Bullish Indifferent…
What 5 Analyst Ratings Have To Say About CARISMA Therapeutics
Within the last quarter, CARISMA Therapeutics (NASDAQ:CARM) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Carisma Announces Latest Data From Phase 1 Clinical Trial Of CT-0508 At 8th Annual CAR-TCR Summit
Group 2 data available to date support primary safety and feasibility endpoints of single-day bolus dosing of CT-0508
New translational analyses combining group 1 & group 2 continue to support CAR-M mechanism
Analyst Ratings for CARISMA Therapeutics
Within the last quarter, CARISMA Therapeutics (NASDAQ:CARM) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday.
Benzinga’s Top Ratings Upgrades, Downgrades For July 6, 2023
Upgrades According to RBC Capital, the prior rating for Repligen Corp (NASDAQ:RGEN) was changed from Sector Perform to…
Carisma Therapeutics Announces First Patient Dosed In Phase 1 Study of CT-0508 In Combination With KEYTRUDA In Patients With HER2 Overexpressing Solid Tumors
Study is designed to evaluate the potential for a synergistic effect of CAR-M therapy in combination with KEYTRUDA®
PHILADELPHIA, June 28, 2023 /PRNewswire/ -- Carisma Therapeutics